Article

Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: a study protocol for an Expanded Access Programme

2022-11-29

Abstract excerpt

<h4>Background: </h4> Monkeypox is a viral zoonotic disease commonly reported in humans in parts of Central and West Africa. This protocol is for an Expanded Access Programme (EAP) to be implemented in the Central African Republic, where Clade I monkeypox virus diseases is primarily responsible for most monkeypox infections. The objective of the programme is to provide patients with confirmed monkeypox with access...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f864b6bf-b1a7-5d79-9764-d1fcec1f687a
DOI: 10.1101/2022.11.28.22282846

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: a study protocol for an Expanded Access ProgrammeDOI 10.1101/2022.11.28.22282846Read

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of CongoSemantic proximity Read

Exploring Monkeypox Virus Treatment: Potential Therapeutic Approaches, and Addressing Current GapsSemantic proximity Read

A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox OutbreakSemantic proximity Read

Recent Advances in Research and Management of Human Monkeypox Virus: An Emerging Global Health ThreatSemantic proximity Read

A systematic review on the global burden of human monkeypox: epidemiology and implications for outbreaksSemantic proximity Read

Vaccine approach for human monkeypox over the years and current recommendations to prevent the outbreak: a rapid reviewSemantic proximity Read

Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreakSemantic proximity Read

Monkeypox Virus Shedding Despite Tecovirimat Treatment in a Cohort in Toronto, Canada.Semantic proximity Read

JYNNEOS VS. ACAM2000: A CRITICAL REVIEW OF THE SAFETY, EFFICACY AND REAL-WORLD EFFECTIVENESS OF MONKEYPOX VACCINESSemantic proximity Read

Efficacy of Tecovirimat and Cidofovir Against MPXV-Induced Pneumonia, Skin Lesion, and Arthritis in the High-Risk Population-Relevant SCID Mouse ModelSemantic proximity Read

Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.Semantic proximity Read

Mechanisms of Tecovirimat Antiviral Activity and Poxvirus ResistanceSemantic proximity Read